Royal Philips has introduced a new at-home, 12-lead electrocardiogram (ECG) integrated solution for decentralised clinical trials.

The patch-based, clinical-grade ECG is claimed to be the first full-service, at-home solution in the industry.

During clinical trials, the device reduces the need for site visits and improves patient recruitment, compliance, and retention.

The company stated that the at-home solution is the new addition to its digitally enabled suite of monitoring solutions.

These solutions help in decentralised clinical trials and improve innovation across the care continuum.

Philips Ambulatory Monitoring and Diagnostics general manager Andy Broadway said: “Our customers are seeking solutions that will help them to address key challenges that can stand in the way of extracting meaningful insights from their clinical trials.

“Our growing portfolio of remote monitoring solutions help to curb patient attrition by reducing the amount of site visits required during the trial period, helping to improve both the quality of the outcome and the patient experience overall.”

The 12-lead ECG solution uses PCA 500 ECG patch data recording technology and helps the participants to record the data with quality that is comparable to the site-based ECGs at home.

The company stated that the innovative body-worn patch of the new solution ensures compliant 12-lead ECG placement.

It also ensures highly secure data transmission without frequent site visits, onsite technicians, or home nurses.

Philips said that the new ECG solution is currently available in select markets in Europe, Asia, and North America.

In November last year, the company signed an agreement to acquire Cardiologs, a French medical technology company, for an undisclosed amount.